Patents by Inventor Yunsong Tong

Yunsong Tong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODULATORS OF THE INTEGRATED STRESS PATHWAY
    Publication number: 20200361941
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Application
    Filed: November 2, 2018
    Publication date: November 19, 2020
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Marina Pliushchev, Jennifer M. Frost, Yunsong Tong, Lawrence A. Black, Xiangdong Xu, Lei Shi, Qingwei I. Zhang, SeungWon Chung, Zhaoming Xiong, Ramzi Farah Sweis, Michael J. Dart, Brian S. Brown, Kathleen J. Murauski
  • Modulators of the integrated stress pathway
    Patent number: 10836725
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: November 17, 2020
    Assignee: AbbVie Inc.
    Inventors: Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei I. Zhang, Yunsong Tong, Charles W. Hutchins, Seungwon Chung, Michael J. Dart
  • MODULATORS OF THE INTEGRATED STRESS PATHWAY
    Publication number: 20200345727
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Application
    Filed: November 2, 2018
    Publication date: November 5, 2020
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Jennifer M. Frost, Marina Pliushchev, Yunsong Tong, Lawrence A. Black, Xiangdong Xu, Lei Shi, Qingwei I. Zhang, SeungWon Chung, Ramzi Farah Sweis, Michael J. Dart, John T. Randolph, Kathleen J. Murauski
  • MODULATORS OF THE INTEGRATED STRESS PATHWAY
    Publication number: 20200347043
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
    Type: Application
    Filed: April 30, 2020
    Publication date: November 5, 2020
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Lei Shi, Kathleen J. Murauski, Xiangdong Xu, Yunsong Tong, John T. Randolph, Michael J. Dart, Hanae Benelkebir, Steven Edeson, Kathryn Starbuck
  • MODULATORS OF THE INTEGRATED STRESS PATHWAY
    Publication number: 20200347033
    Abstract: Provided herein are compounds of Formula (I) or Formula (II), compositions, and methods there of useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
    Type: Application
    Filed: November 2, 2018
    Publication date: November 5, 2020
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, Lei Shi, SeungWon Chung, Zhaoming Xiong, Kathleen J. Murauski, Qingwei I. Zhang, Brian S. Brown, Michael J. Dart
  • MODULATORS OF THE INTEGRATED STRESS PATHWAY
    Publication number: 20190194135
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Application
    Filed: May 5, 2017
    Publication date: June 27, 2019
    Inventors: Carmela Sidrauski, Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei I. Zhang, Yunsong Tong, Charles W. Hutchins, Seungwon Chung, Michael J. Dart
  • MODULATORS OF THE INTEGRATED STRESS PATHWAY
    Publication number: 20190144440
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Application
    Filed: May 5, 2017
    Publication date: May 16, 2019
    Inventors: Carmela Sidrauski, Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei I. Zhang, Yunsong Tong, Charles W. Hutchins, Seungwon Chung, Michael J. Dart
  • MODULATORS OF THE INTEGRATED STRESS PATHWAY
    Publication number: 20190142806
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Application
    Filed: May 5, 2017
    Publication date: May 16, 2019
    Inventors: Carmela Sidrauski, Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei I. Zhang, Yunsong Tong, Charles W. Hutchins, Seungwon Chung, Michael J. Dart
  • MODULATORS OF THE INTEGRATED STRESS PATHWAY
    Publication number: 20190135772
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Application
    Filed: May 5, 2017
    Publication date: May 9, 2019
    Inventors: Carmela Sidrauski, Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei I. Zhang, Yunsong Tong, Charles W. Hutchins, Seungwon Chung, Michael J. Dart
  • Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors
    Patent number: 9796708
    Abstract: Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: October 24, 2017
    Assignee: AbbVie Inc.
    Inventors: Yunsong Tong, Milan Bruncko, Richard F. Clark, Michael Curtin, Alan S. Florjancic, Robin R. Frey, Jianchun Gong, Todd M. Hansen, Zhiqin Ji, Chunqiu Lai, Anthony Mastracchio, Michael Michaelides, Juliem Miyashiro, Roberto M. Risi, Xiaohong Song, Zhi-fu Tao, Keith W. Woods, Guidong Zhu, Thomas Penning, Andrew Souers, Rajeev Goswami, Omprakash Reddy Iguturi, Madhu Babu Dabbeeru
  • Substituted pyrrolo[2,3-d]pyrimindines as CDK9 kinase inhibitors
    Patent number: 9346813
    Abstract: Disclosed are compound of Formula (Ia), wherein R1, R2, and R3 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions, comprising one or more compounds of Formula (Ia).
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 24, 2016
    Assignee: AbbVie Inc.
    Inventors: Alan S. Florjancic, Yunsong Tong, Thomas D. Penning, Andrew J. Souers, Rajeev Goswami, Zhi-Fu Tao
  • Tetracyclic CDK9 kinase inhibitors
    Patent number: 9328112
    Abstract: Disclosed are compounds of Formula (Ia), and pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R3A, R3B, and R4 are as described herein. The compounds may be used as agents in the treatment of diseases, including cancer. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (Ia).
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: May 3, 2016
    Assignee: AbbVie Inc.
    Inventors: Robin Frey, Jane Gong, Zhiqin Ji, Chunqiu Lai, Thomas Penning, Xiaohong Song, Andrew Souers, Yunsong Tong, Gui-Dong Zhu
  • PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS
    Publication number: 20160060257
    Abstract: Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).
    Type: Application
    Filed: March 13, 2014
    Publication date: March 3, 2016
    Applicant: ABBVIE INC.
    Inventors: Yunsong Tong, Milan Bruncko, Richard F. Clark, Michael Curtin, Alan S. Florjancic, Robin R. Frey, Jianchun Gong, Todd M. Hansen, Zhiqin Ji, Chunqiu Lai, Anthony Mastracchio, Michael Michaelides, Juliem Miyashiro, Roberto M. Risi, Xiaohong Song, Zhi-fu Tao, Keith W. Woods, Guidong Zhu, Thomas Penning, Andrew Souers, Rajeev Goswami, Omprakash Reddy Iquturi, Madhu Babu Dabbeeru
  • Pyrrolopyridine inhibitors of kinases
    Patent number: 9181246
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1a, R1b, R1c, X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: November 10, 2015
    Assignee: AbbVie Inc.
    Inventors: Thomas D. Penning, Keith W. Woods, Chunqiu Lai, Alan S. Florjancic, Yunsong Tong
  • TETRACYCLIC CDK9 KINASE INHIBITORS
    Publication number: 20150218165
    Abstract: Disclosed are compounds of Formula (Ia), and pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R3A, R3B, and R4 are as described herein. The compounds may be used as agents in the treatment of diseases, including cancer. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (Ia).
    Type: Application
    Filed: December 12, 2014
    Publication date: August 6, 2015
    Applicant: ABBVIE INC.
    Inventors: Robin Frey, Jianchun Gong, Zhiqin JI, Chunqiu Lai, Thomas Penning, Xiaohong Song, Andrew Souers, Yunsong Tong, Gui-Dong Zhu
  • Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors
    Patent number: 9073922
    Abstract: Disclosed are compounds of Formula (IIIa), wherein R1, R2, R3, X1, X2, X3, X4, X5, have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIIa).
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 7, 2015
    Assignee: AbbVie, Inc.
    Inventors: Jianchun Gong, Zhi-Fu Tao, Thomas D. Penning, Andrew J. Souers, Yunsong Tong, Guidong Zhu
  • CDK9 kinase inhibitors
    Patent number: 8969375
    Abstract: Disclosed are compound of Formula (Ia), wherein R1A, R1, R2, R10, J, L, T, X, Y, and Z are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions, comprising one or more compounds of Formula (Ia).
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: March 3, 2015
    Assignee: AbbVie, Inc.
    Inventors: Chunqiu Lai, Zhi-Fu Tao, Keith W. Woods, Thomas D. Penning, Andrew J. Souers, Anthony Mastracchio, Julie M. Miyashiro, Yunsong Tong
  • PYRROLOPYRIDINE INHIBITORS OF KINASES
    Publication number: 20140357616
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1a, R1b, R1c, X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.
    Type: Application
    Filed: July 28, 2014
    Publication date: December 4, 2014
    Inventors: Thomas D. Penning, Keith W. Woods, Chunqiu Lai, Alan S. Florjancic, Yunsong Tong
  • PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS
    Publication number: 20140275027
    Abstract: Disclosed are compounds of Formula (IIIa), wherein R1, R2, R3, X1, X2, X3, X4, X5, have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIIa).
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Inventors: Jianchun Gong, Zhi-Fu Tao, Thomas D. Penning, Andrew J. Souers, Yunsong Tong, Guidong Zhu
  • PYRROLOPYRIMINDINE CDK9 KINASE INHIBITORS
    Publication number: 20140275004
    Abstract: Disclosed are compound of Formula (Ia), wherein R1, R2, and R3 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions, comprising one or more compounds of Formula (Ia).
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Inventors: Alan S. Florjancic, Yunsong Tong, Thomas D. Penning, Andrew J. Souers, Rajeev Goswami